



## DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies\* to disclose. \*\*Indicates that this individual's presentation(s) **will include** discussion of off-label or unapproved usage.

**Charles J. Dimitroff, M.D.**  
**Guenther Koehne, M.D., Ph.D.**  
**Robert Sackstein, M.D.**

---

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies\* to disclose.

**Adam D. Cohen, M.D.**, faculty for this educational event, is a researcher with Novartis and GlaxoSmithKline. Dr. Cohen is also a consultant with BMS/Celgene, Janssen, Takeda, GlaxoSmithKline, Oncopeptides, AstraZeneca, Seattle Genetics, Roche/Genentech and Arcellx. Dr. Cohen has also received royalties/patent beneficiaries from Novartis. He has indicated that his presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Hagop Kantarjian, M.D.**, faculty for this educational event, is a researcher with Abbvie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis and Pfizer. Dr. Katarjian is also a speaker with Abbvie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical Ltd. And Nova. Dr. Kantarjian has indicated that his presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Paul Lin, M.D.**, faculty for this educational event has received grant/research support from Takeda and has received royalties from Takeda. Dr. Lin has indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Matthew J. Matasar, M.D.**, faculty for this educational event has received research funding from Genentech, Roche GlaxoSmithKline, IGM Biosciences, Bayer, Pharmacyclics, Janssen, Rocket Medical, Seattle Genetics and Immunovaccine Technologies. Dr. Matasar is also a consultant with Genentech, Bayer, Merck, Juno Therapeutics, Roche, Teva, Rocket Medical, Seattle Genetics, DaiichiSankyo and Takeda. Dr. Matasar is an advisor with Genentech, Bayer, Merck, Juno Therapeutics, Roche, Teva, ROcket Medical, Seattle Genetics, Daiichi Sankyo and Takeda. Dr. Matasar has individual stocks/stock options with Merck. Dr. Matasar has indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Siddhartha Mukherjee, M.D.**, faculty for this education event is a consultant with Immuneel Therapeutics, Pure Tech, Cellenkos, and Brahma Therapeutics. He has also received individual socks/stock option from VOR. Dr. Mukherjee has indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Raajit K. Rampal, M.D., Ph.D.**, faculty for this educational event has received research funding from Incyte, Constellation, Stemline and Zentalis. Dr. Rampal is also a consultant with Morphosys/Constellation, Incyte, CTI, Celgene/BMS, Novartis, Promedior, Blueprint, Stemline, Galaecto, Pharmessentia, Abbvie and Sierra Oncology. Dr. Rampal has indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Paul G. Richardson, M.D.**, faculty for this educational event has received research funding from Oncopeptides, Celgene/BMS, Takeda and Karyopharm. Dr. Richardson is also a consultant with Oncopeptide, Celgene/BMS, Takeda, Janssen, Sanofi, GSK, Regeneron and Astra Zeneca. Dr. Richardson has indicated that his presentation will

not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Michel Sadelein, M.D.**, faculty of this educational activity, has received research funding from Takeda Therapeutics, Atarabio, Fate Therapeutics and Mnemo. Dr. Sadelein indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Craig Sauter, M.D.**, faculty for this educational event has received research funding from Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals and Sanofi-Genzyme. Dr. Sauter is an advisor with Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company and Celgene. Dr. Sauter has indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Robert Soiffer, M.D.**, faculty for this education event is a consultant with Cugene, Takeda, Jasper, Jazz Pharmaceuticals, Precision Biosciences, Alexion and Rheos Therapeutics. He is also on the board of directors with NMPD – Be the Match and Kiadis. He has also a part of career development award committee for Gilead. Dr. Soiffer has indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Eytan M. Stein, M.D.**, faculty for this education event has received research funding from Syndax, Novartis, Servier, BMS, Foghorn, Gilead and Syros. Dr. Stein is a consultant with Syndax, Novartis, Jazz, Foghorn, BMS, Gilead, Abbvie and Genentech. Dr. Stein has indicated that his presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Wendy Stock, M.D.**, faculty for this education event is an advisor for Jazz, Kite, Pfizer and Syndax. She has indicated that his presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Richard Stone, M.D.**, faculty for this education event is a consultant with Abbvie, Actinium, Arog, BMS, Boston Pharmaceuticals, GSK, Janssen, Jazz, Novartis, Syros Takeda, Elevate Bio, Syndax and Syntrix Geomol. He has indicated that his presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

**Marcel R. van den Brink, M.D.**, faculty for this education event is researcher with Seres Therapeutics. Dr. van den Brink is a consultant with Merck & Co, Magenta Therapeutics, WindMIL Therapeutics, Frazier Healthcare Partners, Nektal Therapeutics and Forty. Dr. van den Brink is an advisor with Rheos and GSK. He has received royalties or patent benefits from Wolters Kluwer. He has an executive role with DKMS as a chairman. He has individual stocks/stock options with Seres Therapeutics, Notch Therapeutics and Pluto Therapeutics. He has indicated that his presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

All of the relevant financial relationships listed for these individuals have been mitigated.

---

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies\*.

---

*\*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*